Mirikizumab Market
The market for Mirikizumab was estimated at $143 million in 2024; it is anticipated to increase to $439 million by 2030, with projections indicating growth to around $1.12 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Mirikizumab Market Outlook
Revenue, 2024
$143M
Forecast, 2034
$929M
CAGR, 2025 - 2034
20.6%
The Mirikizumab industry revenue is expected to be around $172.2 million in 2025 and expected to showcase growth with 20.6% CAGR between 2025 and 2034. The Mirikizumab market demonstrates strong expansion because of its expanding importance in medical practice. The market expansion of Mirikizumab stems from two main factors: the increasing number of inflammatory bowel disease cases and the positive clinical trial results for treating ulcerative colitis and Crohns disease. The market value of Mirikizumab increases because of scientific research and its potential to revolutionize psoriasis treatment and its established effectiveness in treating inflammatory bowel diseases.
The monoclonal antibody Mirikizumab functions as an interleukin 23 targeting agent which plays a crucial role in both inflammatory and infectious immune responses. The main therapeutic uses of Mirikizumab focus on treating autoimmune diseases through its effectiveness against inflammatory bowel diseases and psoriasis.
Market Key Insights
- The Mirikizumab market is projected to grow from $142.8 million in 2024 to $929 million in 2034. This represents a CAGR of 20.6%, reflecting rising demand across Treatment of Psoriasis and Management of Crohn's Disease.
- Eli Lilly & Co. Ltd. is the sole producer in this market, holding full control over supply and pricing.
- U.S. and Germany are the top markets within the Mirikizumab market and are expected to observe the growth CAGR of 19.8% to 28.8% between 2024 and 2030.
- Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 15.5% to 21.4%.
- The complete eco-system of the Mirikizumab market is becoming more attractive for investment due to transitions such as Revolutionizing Treatment for Psoriasis. These changes are expected to create a positive cycle that supports growth and adds an estimated $69 million in value between 2025 and 2030.
- The Mirikizumab market is set to add $787 million between 2024 and 2034, with manufacturer targeting Retail Pharmacies & Online Pharmacy Distribution Channels projected to gain a larger market share.
- With Rising prevalence of autoimmune diseases, and Increased r&d in biologics, Mirikizumab market to expand 551% between 2024 and 2034.
Opportunities in the Mirikizumab
Strategic partnerships for drug development will also drive mirikizumab market growth through new market opportunities. The combination of biopharmaceutical companies through partnerships will speed up clinical trials and regulatory approval processes which will expand mirikizumab market reach and availability.
Growth Opportunities in North America and Europe
The advanced healthcare system of North America combined with its high rates of inflammatory bowel diseases creates substantial market potential for mirikizumab. The United States leads the way in clinical trials and innovative treatments which drives demand for mirikizumab because of its strong focus on new therapeutic options. The market faces intense competition because Pfizer and Johnson & Johnson maintain their position as leading market players. The FDA approval of mirikizumab will introduce a fresh treatment choice to patients while reshaping the existing market dynamics. The rising number of autoimmune disease cases in this region requires the development of innovative treatments including mirikizumab.
The European healthcare sector with its developed systems and high spending levels creates major potential for mirikizumab market expansion. The European region maintains a strong focus on research development through its leading nations Germany and the UK which drives up demand for mirikizumab. The market shows strong competition because Roche and Novartis maintain dominant positions among pharmaceutical companies. The European Medicines Agency approval of mirikizumab would establish a competitive market position. The expanding number of patients with chronic inflammatory diseases in this region drives the demand for mirikizumab as an effective treatment solution.
Market Dynamics and Supply Chain
01
Driver: Rising Prevalence of Inflammatory Bowel Diseases and Advancements in Biologic Therapies
The worldwide increase in inflammatory bowel disease cases also creates a substantial market opportunity for mirikizumab. The monoclonal antibody mirikizumab shows promise as an IBD treatment because it targets IL 23 which plays a role in inflammation during clinical trials. The market also experiences growth because of new developments in biologic therapy treatments. The biopharmaceutical industry has also developed innovative drugs through targeted autoimmune disorder research which has also resulted in the creation of mirikizumab and similar promising treatments.
The growing investment in drug research and development activities supports the growth of mirikizumab. Pharmaceutical companies dedicate major funding to discover new treatments for chronic diseases. The current market trend of increased investment will also speed up the development process of mirikizumab which will also lead to its wider market availability.
02
Restraint: High Development Costs and Regulatory Hurdles
The development of mirikizumab alongside other new biologics needs major financial backing. The high expenses from clinical trials and manufacturing and regulatory approval procedures create major obstacles for developers. The high costs of development result in elevated product prices which restrict both market entry and customer reach. The pharmaceutical industry faces additional challenges because of its strict regulatory framework which extends the time needed for product approval and affects market competition.
03
Opportunity: Rising Prevalence of Inflammatory Bowel Diseases Globally and Expansion in Emerging Markets
The worldwide rise of inflammatory bowel diseases creates a growing market for mirikizumab. The market for mirikizumab as an IBD treatment will experience significant expansion because of rising patient requirements for effective therapeutic solutions. The development of biopharmaceuticals through technological progress drives this market expansion.
The growth prospects for mirikizumab appear strong in emerging markets including India and China because their healthcare industries continue to expand. The growing interest in IBD treatments together with rising healthcare spending in these areas will boost market demand for this innovative therapeutic.
04
Challenge: Potential Side Effects and Safety Concerns
The market potential of mirikizumab for treating different inflammatory diseases faces challenges because of its possible adverse effects and safety risks. The identification of adverse events or safety problems during clinical trials will trigger regulatory body attention which may result in delayed product approval or complete product removal from the market. The market demand for mirikizumab together with healthcare provider and patient safety perceptions will experience negative effects from any adverse events or safety issues that occur during clinical trials.
Supply Chain Landscape
1
API Production
Eli Lilly and CompanyRoche Holding AG
2
Formulation & Development
Eli Lilly & Co. Ltd.
3
Packaging & Labelling
Johnson & Johnson Services IncEli Lilly and Company
4
Distribution & Sales
AstraZeneca PLCEli Lilly and Company
1
API Production
Eli Lilly and CompanyRoche Holding AG
2
Formulation & Development
Eli Lilly & Co. Ltd.
3
Packaging & Labelling
Johnson & Johnson Services IncEli Lilly and Company
4
Distribution & Sales
AstraZeneca PLCEli Lilly and Company
Use Cases of Mirikizumab in Treatment of Psoriasis & Management of Crohn's Disease
Treatment of Psoriasis : The monoclonal antibody mirikizumab serves as a common treatment for patients with psoriasis. The treatment works by focusing on interleukin 23 which drives psoriasis development to decrease inflammation and control excessive skin cell growth. Mirikizumab stands out in psoriasis treatment because it delivers sustained symptom relief to patients. Eli Lilly and Company maintains its leading market position through mirikizumab success in clinical trials which proves the drugs effectiveness.
Management of Crohn's Disease : The drug Mirikizumab demonstrates effectiveness for treating Crohns disease which belongs to inflammatory bowel disease category. The drug functions by blocking interleukin 23 to decrease digestive tract inflammation. The main benefit of mirikizumab for Crohns disease treatment lies in its ability to create and sustain remission in patients with moderate to severe disease. The leading companies including Eli Lilly and Company have studied mirikizumab extensively to prove its effectiveness and safety when treating Crohns disease.
Recent Developments
Pharmaceutical companies have been advancing the development of Mirikizumab as their new monoclonal antibody treatment. The pharmaceutical industry has shown growing interest in mirikizumab because of its demonstrated ability to treat psoriasis and ulcerative colitis. The pharmaceutical industry has experienced rising demand for effective treatments of these diseases because of this emerging market trend. The medical field continues to study mirikizumab through clinical trials to determine its potential applications beyond its current uses.
December 2024 : The pharmaceutical company Eli Lilly and Company announced positive results from phase III clinical trials which demonstrated mirikizumab effectively treats moderate to severe ulcerative colitis.
October 2024 : The U.S. FDA granted fast track designation to mirikizumab for Crohns disease treatment through a request from Eli Lilly and Company.
July 2024 : The pharmaceutical company Eli Lilly and Company announced positive early results from their phase II clinical trial of mirikizumab in psoriasis patients which suggests the drug could treat additional conditions.
Impact of Industry Transitions on the Mirikizumab Market
As a core segment of the Pharmaceutical industry,
the Mirikizumab market develops in line with broader industry shifts.
Over recent years, transitions such as Revolutionizing Treatment for Psoriasis and Advancing Gastrointestinal Therapies have redefined priorities
across the Pharmaceutical sector,
influencing how the Mirikizumab market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Revolutionizing Treatment for Psoriasis
The monoclonal antibody Mirikizumab brings a new approach to psoriasis treatment through its mechanism of action. The drug shows promise as a treatment because it specifically targets interleukin 23 which plays a central role in psoriasis development. The drug has demonstrated outstanding results in clinical trials which has led to a new approach for treating moderate to severe plaque psoriasis. Pharmaceutical companies now direct their research efforts toward maximizing mirikizumab benefits for patients through development initiatives.
02
Advancing Gastrointestinal Therapies
The therapeutic applications of Mirikizumab reach further than skin conditions. The pharmaceutical industry now uses Mirikizumab as a new treatment for inflammatory bowel diseases which affect patients with Crohns disease and ulcerative colitis. The addition of mirikizumab to IBD treatment protocols will enhance patient outcomes and life quality thus creating a major shift in the gastrointestinal therapeutics market. The growing interest in Mirikizumab has led companies to conduct more clinical trials and form partnerships which advances the industry as a whole.